Showing results (561-570 of 607) with videos related to

Sort By:
Pageof 61
Pharmacoeconomics - Open|October 8, 2024
Cost Effectiveness of Sequencing Vedolizumab as First-Line Biologic in Ulcerative Colitis and Crohn's Disease in Canada: An Analysis Using Real-World Evidence from the EVOLVE StudyAren Fischer, Stephen Mac, Erica Stivelman Freiman, et al.
Pharmacoeconomics - Open|August 5, 2024
Health Technology Assessment Reports for Non-Oncology Medications in Canada from 2018 to 2022: Methodological Critiques on Manufacturers' Submissions and a Comparison between Manufacturer and Canadian Agency for Drugs and Technologies in Health (CADTH) AnalysesFatemeh Mirzayeh Fashami, Jean-Eric Tarride, Behnam Sadeghirad, et al.
Pharmacoeconomics - Open|July 9, 2024
Using a Patient-Centered Multicriteria Decision Analysis to Assess the Value of Multiple Sclerosis Treatments in the US: A Study ProtocolSurachat Ngorsuraches, Tim C Lai, Rebecca Habermann, et al.
Pharmacoeconomics - Open|July 5, 2024
Psychometric Properties of the EQ-5D-5L in Patients with Alopecia AreataAndrew Lloyd, Daniel Aggio, Caleb Dixon, et al.
Pharmacoeconomics - Open|August 28, 2024
Clinicians' Preferences for Sphingosine-1-Phosphate Receptor Modulators in Multiple Sclerosis Based on Clinical Management Considerations: A Choice ExperimentAlexander Keenan, Chiara Whichello, Hoa H Le, et al.
Pharmacoeconomics - Open|May 2, 2024
Cancer-Specific Health Utilities: Evaluation of Core Measurement Properties of the EORTC QLU-C10D in Lung Cancer Patients-Data from Four Multicentre LUX-Lung Trials, Applying Six Country TariffsMicha J Pilz, Simone Seyringer, Imad Al-Naesan, et al.
Pharmacoeconomics - Open|June 10, 2024
Cost-Effectiveness of Vedolizumab as a First-Line Advanced Therapy Versus Adalimumab Treatment Sequences for Ulcerative Colitis in ItalyJonathan Salcedo, Daniel Hill-McManus, Chloë Hardern, et al.
Pharmacoeconomics - Open|May 18, 2024
Public Preference for Financing Preventive Vaccines in Health Shocks: The Case of COVID-19 Vaccines in a Middle-Income CountryNajmeh Moradi, Leila Zarei, Narges Hajimoladarvish, et al.
Pharmacoeconomics - Open|April 17, 2024
Cost of Care for Non-communicable Diseases: Which Types of Healthcare Providers are the Most Economical in India's Chhattisgarh State?Samir Garg, Narayan Tripathi, Kirtti Kumar Bebarta
Pharmacoeconomics - Open|April 11, 2024
Updated Public Health Impact and Cost Effectiveness of Recombinant Zoster Vaccine in Canadian Adults Aged 50 Years and OlderSydney George, Justin Carrico, Katherine A Hicks, et al.
Pageof 61